Magnesium for the Prevention of Kidney Damage in Patients with Mesothelioma Undergoing Surgery with Hyperthermic Intraoperative Cisplatin

Inclusion Criteria

• Adult patients (>=18 years old) with malignant mesothelioma undergoing surgery with HIOC with Dr. Raphael Bueno or another Brigham and Women’s Hospital (BWH) thoracic surgeon

Exclusion Criteria

• Estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m^2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Screening labs refer to those obtained at the preoperative visit with the surgeon or within 90 days prior, whereas preoperative labs are obtained on the day of admission (or one to seven days prior to surgery)
• Serum Mg > 3 mg/dl on either screening labs or preoperative labs
• Pregnant/breastfeeding
• Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myositis), as hypermagnesemia can predispose to muscle weakness and decreased respiratory drive
• Coronary artery disease, defined as any of the following in the prior year: a positive stress test; coronary angiogram indicating 1 or more vessels with > 70% stenosis; percutaneous coronary intervention with stents; or coronary artery bypass graft surgery
• Sinus bradycardia, defined as a heart rate (HR) < 55 beats per minute (bpm) detected on any resting 12-lead electrocardiogram (ECG) in the preceding 6 months
• High grade atrioventricular (AV) block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker
• Positive coronavirus disease (COVID) test in the 10 days prior to surgery
• Prisoner
• Hypersensitivity to Mg sulfate
• Concurrent participation in a study with an alternative experimental therapy that may interact with IV Mg
• Any condition that, in the view of the principal investigator (PI), might place the patient at increased risk or compromise the integrity of the study
• Conflict with other study